Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Electroconvulsive Therapy01:30

Electroconvulsive Therapy

200
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
200
Parenteral Anesthetics: Overview01:24

Parenteral Anesthetics: Overview

203
Intravenous anesthetics are drugs administered parenterally to induce anesthesia or sedation. Propofol is a widely used agent formulated as a 1% emulsion in soybean oil, glycerol, and egg phosphatide. It induces rapid anesthesia primarily due to its rapid distribution from the bloodstream to target tissues and is metabolized in the liver. However, it can cause significant pain on injection and hypertriglyceridemia. Fospropofol, a water-based prodrug of propofol, lacks these adverse effects.
203
Sedatives and Hypnotics Drugs: Miscellaneous Agents01:17

Sedatives and Hypnotics Drugs: Miscellaneous Agents

247
Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
247
Sedatives and Hypnotics: Overview01:23

Sedatives and Hypnotics: Overview

670
Sedatives are drugs that alleviate anxiety, while hypnotics induce sleep. Both classes of medication suppress neuronal activity, leading to a calming effect for sedatives and facilitating sleep for hypnotics.
Sedative-hypnotics are categorized into barbiturates, benzodiazepines (BZDs), and non-benzodiazepines or Z-drugs. These drugs work by suppressing central nervous system activity, and this suppression is dose-dependent. Older sedative medications, like barbiturates, follow a linear curve in...
670
Depression: Overview01:18

Depression: Overview

361
Depression is a prevalent mental illness marked by persistent sadness and lack of interest in previously enjoyable activities. It can take several forms, including major depression, persistent depressive disorder, and bipolar I and II disorders. Symptoms range from emotional changes like chronic worry to physical changes like sleep disturbances and suicidal thoughts. From a neurobiological perspective, depression is believed to be triggered by abnormalities in the brain's prefrontal cortex,...
361
Depressants01:28

Depressants

182
Depressant drugs, including alcohol and sedative-hypnotics, diminish central nervous system activity by enhancing the action of gamma-aminobutyric acid (GABA), a neurotransmitter that reduces brain activity and promotes relaxation. These substances can have various therapeutic uses but also pose significant risks, especially when misused or combined.
Alcohol is a common depressant that can induce a sense of relaxation and reduced inhibition at low doses. Contrary to its occasional...
182

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A systematic review of the pharmacokinetics of classical serotonergic psychedelic compounds in healthy adult subjects.

Journal of psychopharmacology (Oxford, England)·2026
Same author

Regional Blood Flow Signatures of Opioidergic Modulation of Ketamine in Major Depressive Disorder: A Randomized Crossover Study.

The American journal of psychiatry·2026
Same author

Effect of naltrexone pretreatment on ketamine-induced glutamatergic activity and symptoms of depression: a randomized crossover study.

Nature medicine·2025
Same author

Guidelines for ketamine use in clinical psychiatry practice.

BJPsych open·2024
Same author

Association of Hallucinogen Persisting Perception Disorder with Trait Neuroticism and Mental Health Symptoms.

Journal of psychoactive drugs·2023
Same author

Effects of gamma frequency binaural beats on attention and anxiety.

Current psychology (New Brunswick, N.J.)·2023
Same journal

Continuous theta burst stimulation to the frontal pole durably decreases medial frontoamygdala connectivity.

International review of psychiatry (Abingdon, England)·2026
Same journal

What are the arguments for and against recognizing 'terminal' anorexia nervosa? A narrative review.

International review of psychiatry (Abingdon, England)·2026
Same journal

Behavioral addictions in adolescents in Latin America: a narrative review of prevalence, mental health comorbidities, and gaps in care.

International review of psychiatry (Abingdon, England)·2026
Same journal

Persistent suicidality: a concept analysis using Rodgers' evolutionary approach.

International review of psychiatry (Abingdon, England)·2026
Same journal

Extending the evidence for Scrambler Therapy to reduce pain in chemotherapy-induced peripheral neuropathy.

International review of psychiatry (Abingdon, England)·2026
Same journal

Medical assistance in dying and palliative care in Canada: clinical and ethical considerations in an evolving landscape.

International review of psychiatry (Abingdon, England)·2026
See all related articles

Related Experiment Video

Updated: Sep 16, 2025

Author Spotlight: Therapeutic Benefit of Closed-Loop Deep Brain Stimulation in Depression Treatment
05:19

Author Spotlight: Therapeutic Benefit of Closed-Loop Deep Brain Stimulation in Depression Treatment

Published on: July 7, 2023

2.5K

Ketamine for depression.

Luke A Jelen1,2, James M Stone1,2

  • 1Centre for Affective Disorders, Department of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, United Kingdom.

International Review of Psychiatry (Abingdon, England)
|February 11, 2021
PubMed
Summary
This summary is machine-generated.

Ketamine, an NMDA receptor antagonist, shows rapid antidepressant effects for treatment-resistant depression (TRD). Further research is needed to address side-effects, abuse potential, and optimize long-term treatment strategies.

Keywords:
(S)-ketamineKetamineantidepressantdepressionmechanism of action

More Related Videos

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression
04:29

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression

Published on: January 7, 2019

28.9K
A Guide to In vivo Single-unit Recording from Optogenetically Identified Cortical Inhibitory Interneurons
10:32

A Guide to In vivo Single-unit Recording from Optogenetically Identified Cortical Inhibitory Interneurons

Published on: November 7, 2014

19.3K

Related Experiment Videos

Last Updated: Sep 16, 2025

Author Spotlight: Therapeutic Benefit of Closed-Loop Deep Brain Stimulation in Depression Treatment
05:19

Author Spotlight: Therapeutic Benefit of Closed-Loop Deep Brain Stimulation in Depression Treatment

Published on: July 7, 2023

2.5K
Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression
04:29

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression

Published on: January 7, 2019

28.9K
A Guide to In vivo Single-unit Recording from Optogenetically Identified Cortical Inhibitory Interneurons
10:32

A Guide to In vivo Single-unit Recording from Optogenetically Identified Cortical Inhibitory Interneurons

Published on: November 7, 2014

19.3K

Area of Science:

  • Neuroscience
  • Psychiatry
  • Pharmacology

Background:

  • Ketamine, an N-Methyl-D-Aspartate (NMDA) receptor antagonist, is a dissociative anesthetic with emerging use in treating depression.
  • It demonstrates rapid antidepressant effects, offering a novel therapeutic avenue for treatment-resistant depression (TRD).

Purpose of the Study:

  • To review the history, pharmacology, and clinical evidence of ketamine for depression.
  • To summarize potential adverse effects and explore neurobiological mechanisms of ketamine's antidepressant action.
  • To outline future research directions for optimizing ketamine therapy and developing next-generation antidepressants.

Main Methods:

  • Literature review of ketamine's history, pharmacology, and clinical applications in psychiatry.
  • Synthesis of clinical evidence regarding ketamine's efficacy and safety in treating depression.
  • Exploration of proposed neurobiological mechanisms and future research needs.

Main Results:

  • Ketamine, particularly (S)-ketamine, shows rapid and robust antidepressant effects in TRD.
  • Challenges include maintaining response, managing side-effects, and potential for abuse.
  • The review summarizes clinical data, adverse effects, and proposed mechanisms.

Conclusions:

  • Ketamine offers a promising rapid-acting treatment for TRD, but challenges remain.
  • Further research is crucial for identifying biomarkers, optimizing treatment, and developing safer alternatives.
  • Understanding neurobiological pathways is key to advancing antidepressant therapies.